Redoxis is a Swedish CRO that specializes in in vivo animal models for preclinical drug efficacy validation as well as ex vivo and in vitro models for investigation of MoA.
Our main disease models are those of autoimmunity and chronic inflammation where we have both conventional models and cutting-edge developed models. With a focused area of disease models, and an efficient and competent crew of researchers, we provide world-leading studies in a professional manner, with speed, flexibility and high value for the investment.

Our major in vivo disease models includes models of
*Rheumatoid arthritis

• Mouse collagen-induced arthritis
• Rat collagen-induced arthritis
• Rat Pristane-induced arthritis
• Mouse Collagen Antibody induced arthritis
• Mouse Glucose-6-Phosphate Isomerase induced arthritis
• Rat adoptive T cell transfer
  *Monoarthritis
  *Multiple sclerosis
• Rat spinal cord homogenate induced EAE
• Rat MOG1-125 induced EAE
• Rat MBP induced EAE
• Mouse MOG35-55 induced EAE
• Mouse PLP induced EAE
  *Guillain Barré syndrome
  *Systemic Lupus
• Spontaneous models
• Induced models
  *Psoriasis/Psoriasisarthritis
• Imiquimod (IMQ) induced psoriasis in mice
• Mannan induced psoriatic arthritis (MiP)
  *Acute inflammation sepsis (LPS induced)
  *Gout
  *Models of Parkinson´s disease

With our fully equipped lab, we can perform most immunology assays and are used to set up and validate new models on-demand with methods including ELISA, Luminex, Flow cytometry, chemotaxis, viability, NOX2 activity.

We also routinely perform PK studies, safety studies and organ or sample collections.

Redoxis has recently set up a Class II lab for custom-made viral vector studies.